Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study-Reference-Cited by-同舟云学术

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study

Published:2019-05-24 Issue:1 Volume:110 Page:77-85
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Matsumoto Yosuke^ORCID, ,Kobayashi Tsutomu,Shimura Yuji,Kawata Eri,Nagoshi Hisao,Ohshiro Muneo,Sugitani Mio,Shimura Kazuho,Iwai Toshiki,Fuchida Shin-ichi,Yoshida Mihoko,Kiyota Miki,Mizutani Shinsuke,Chinen Yoshiaki,Takimoto-Shimomura Tomoko,Nakao Mitsushige,Kaneko Hiroto,Uchiyama Hitoji,Uoshima Nobuhiko,Nishigaki Hikari,Kobayashi Yutaka,Horiike Shigeo,Shimazaki Chihiro,Taniwaki Masafumi,Kuroda Junya

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-019-02650-w.pdf

Reference21 articles.

1. Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Japanese Bendamustine Lymphoma Study Group, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2059–64.

2. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, NCI Sponsored International Working Group, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244–53.

3. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

4. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–9.

5. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–9.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects;Critical Reviews in Oncology/Hematology;2023-10

2. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience;Leukemia & Lymphoma;2022-10-12

3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia;Neoplasia;2021-04

4. MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway;OncoTargets and Therapy;2021-03

5. Cytomegalovirus Reactivation After Bendamustine-Based Chemotherapy;Infectious Diseases in Clinical Practice;2021-02-19